is currently being evaluated in the ABOYA-119 clinical trial as monotherapy in patients with advanced solid tumors having at least one mutation in a defined panel of DNA damage response (DDR ...

It also givessolution of supporting different part number of established DDR vendors like Micron, Elpida, Samsung etc. Access to off-chip DDR SDRAM has been an integral part of behavioural design for ...

The Company’s lead ATR inhibitor, ATRN-119, is currently being evaluated in the ABOYA-119 clinical trial as monotherapy in patients with advanced solid tumors having at least one mutation in a defined ...

DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical ...

The Company's lead ATR inhibitor, ATRN-119, is currently being evaluated in the ABOYA-119 clinical trial as monotherapy in patients with advanced solid tumors having at least one mutation in a defined ...